In this Nutritional Outlook interview, Dr. Sybille Buchwald-Werner shares her board perspective on Oceanium’s platform-driven approach to seaweed bioactives and disciplined global expansion.
Rather than building around a single ingredient, Oceanium is structured as a circular bioactive platform designed for long-term resilience, capital efficiency, and scientific discipline. The discussion explores how governance, regulatory realism, and dose-efficient innovation help protect trust in a nutraceutical market often driven by short-term trends.
From sustainability integration to US market readiness, the conversation highlights how science functions not only as a research tool, but as a strategic decision framework at board level — guiding where to invest, where to scale, and where to exercise restraint.
